Business
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected in Q4 2025 - - Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward - - Capital raise provides operational runway through Q1 2026 - ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechn
About this update from Dogwood Therapeutics, Inc.
[{"type":"image","alt":"Dogwood Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dogwood Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ymONq2rYrZZXJkVRmE8SRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f","width":300,"height":300}},"lazy":false},{"type":"text","content":"-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial -","length":138,"tagName":"p"},{"type":"text","content":"- Halneuron® CINP P2b study interim data readout is expected in Q4 2025 -","length":73,"tagName":"p"},{"type":"text","content":"- Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward -","length":93,"tagName":"p"},{"type":"text","content":"- Capital raise provides operational runway through Q1 2026 -","length":61,"tagName":"p"},{"type":"text","content":"ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024.","length":310,"tagName":"p"},{"type":"text","content":"“We have made considerable progress in advancing our flagship Halneuron® CINP Phase 2b study, with interim data expected by year end. We have also significantly improved our balance sheet and liquidity over the past few months, improving our cash position in a recent capital raise along with the agreement of our largest shareholder to exchange all their outstanding loan amounts for equity,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. “We believe this substantial organizational progress, in the context of future milestones, positions Dogwood as a more attractive investment opportunity moving forward.”","length":630,"tagName":"p"},{"type":"text","content":"Key Highlights","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Company commenced dosing in its Halneuron® Phase 2b CINP program this month, with p...